ratio against strains contained in the vaccine of the order 70-90% (9) . An oral, live adenovirus vaccine containing types 4 and 7 has been prepared and routinely used in the successful control of these infections in recruit populations (10, 11) . A meningococcal vaccine against types A and C has been developed at the Walter Reed Army Institute of Research, its effectiveness has been demonstrated in military personnel, and it now is routinely employed on entry into the service (12, 13) .
Streptococcal infections have been controlled in some settings by use of long acting penicillin administered on arrival in recruit training (2) . Mycoplasma pneumoniae remains a major challenge to both civilian and military populations (15) , although trials of some vaccine preparations have proved promising (15, 16) . However, there is evidence that an inactivated vaccine may induce cell-mediated but not humoral immunity in sero-negative individuals (17) .
The purpose of this symposium is to review the current experiences of the three services in the U.S. Armed Forces with acute respiratory illnesses, including the recent experience in Viet Nam, to detail the advances made with adenovirus and meningococcal vaccines, and to demonstrate the usefulness of serological surveys in investigating respiratory infections in South American recruits. We are fortunate in having some of the major developers of these vaccines with us as well as other distinguished investigators of respiratory disease in military personnel.
